

Follow-up of growth and puberty in children with premature adrenarche

Jani Liimatta^{1,2}, Pauliina Utriainen¹, Raimo Voutilainen^{1,2} and Jarmo Jääskeläinen^{1,2} ¹University of Eastern Finland, ²Kuopio University Hospital Disclosure statement: Nothing to disclose



BACKGROUND

METHODS

Children with premature adrenarche (PA) have enhanced prepubertal growth in height and they are more often overweight than healthy peers (1). Insulinlike growth factors (IGF) play a role in pubertal initiation (2) and elevated serum IGF-1 levels have been reported in children with PA (1,3). Earlier menarcheal timing has been reported in girls with premature

Seventy-three PA children and 99 healthy controls were originally recruited into this study. Other causes of hyperandrogenism were excluded. Birth data were collected from medical records. Laboratory samples were taken at diagnosis/ first study examination at the mean age of 7.6 years. Altogether 61.6 % participated (36 PA, 52 control girls; 7 PA, 11 control boys) in the follow-up study including the assessment of anthropometric measures and pubertal status at the mean age of 12.1 years. Pubertal status was assessed by Tanner staging scores. Birth length SDS, birth weight SDS, height SDS and BMI SDS were calculated with current Finnish growth references. All statistical analyses were performed with the SPSS 21.0 software (SPSS Inc., Chicago, IL). Mann Whitney U (a) and independent samples t-test (b) were used to analyse differences in continuous parameters between the study groups. χ^2 -test was used to evaluate statistical differences in the number of subjects with attainment of certain pubertal stage. Possible predictors of earlier menarche were analyzed by logistic regression.

pubarche and PA (4,5).

Figure 1. Pubertal development in 12-year-old PA and control girls and boys.

RESULTS

Cohort characteristics (here for girls only) at birth, at baseline (mean age 7.6 years) and at 12 years are presented in Table 1. At the current follow-up examination, the PA girls but not the boys were taller and heavier than the controls. A trend towards more advanced pubertal development was seen in all PA subjects (Figure 1) but only menarche and pubarche in girls reached statistical significance between the groups (Figure 2). The same percentages of the PA and control boys were at Tanner genital stage ≥ 2 (Figure 2). In a univariate logistic regression model, having a history of PA, earlier maternal menarche, higher childhood BMI, serum DHEAS, androstenedione, IGF1, and insulin concentrations were all associated with the earlier appearance of menarche. However, in a multivariate stepwise forward model, only the history of PA, earlier maternal menarche, and higher IGF-1 were significantly associated with early menarche (Table 2).


OBJECTIVE

The aim of this follow-up cohort study was growth evaluate and pubertal to children. in PA We development hypothesized that children with PA have earlier pubertal development than healthy Also prepubertal controls. factors predicting earlier menarche were investigated.


Table 1. Characteristics of all girls at birth (A), at the age of 7 years (B) and at the age of 12 years (C). Values are expressed as mean (95% CI). No statistical differencies were seen in boys.

Girls Control (n=52) p PA (n=36)





Pubic hair development (Tanner P scale 1-5)



(weeks)(39.1-40.4) \mathbb{N}^{S^4} (39.1-40.7)Birth weight (kg) 3.48 (3.30-3.66) \mathbb{N}^{S^4} 3.41 (3.18-3.63)Birth length (cm) 50.2 (49.5-50.9) \mathbb{N}^{S^6} 49.4 (48.5-50.4)B -0.16 (-0.46-0.14) -0.001^{10} 1.02 (0.64-1.40)Age (yr) 7.5 (7.3-7.7) \mathbb{N}^{S^6} 7.6 (7.3-7.8)Height SDS -0.16 (-0.46-0.14) 0.001^{10} 1.02 (0.64-1.40)BMI SDS 0.18 (-0.11-0.47) 0.001^{10} 1.04 (0.65-1.43)DHEAS (µmol/1) 0.94 (0.79-1.09) 0.001^{10} 2.33 (1.94-2.72)Androstenedione (nmol/1) 1.65 (1.39-1.92) 0.001^{10} 3.18 (2.71-3.66)Insulin (mU/1) 4.83 (4.03-5.63) 0.01^{10} 5.98 (5.14-6.83)IGF-1 (nmol/1) 20.3 (18.5-22.1) 0.01^{10} 25.3 (22.7-27.9)C -0.08 (0.35-0.20) 0.001^{10} 160.1 (157.4-162.9)Height (cm) 153.3 ($0.35-0.20$) 0.001^{10} 0.88 ($0.48-1.28$)Weight (kg) 45.4 ($42.6-48.2$) 0.001^{10} 56.0 ($51.4-60.6$)	A		Г	
Birth weight (kg) $(3.30-3.66)$ NS ^a $(3.18-3.63)$ Birth length (cm) 50.2 ($49.5-50.9$) NS ^a 49.4 ($48.5-50.4$) B I I I Age (yr) 7.5 ($7.3-7.7$) NS ^a 7.6 ($7.3-7.8$) Height SDS 0.016 ($0.04-0.14$) 0.001^{a} 1.02 ($0.64-1.40$) BMI SDS 0.18 ($0.11-0.47$) 0.001^{a} 2.33 ($1.94-2.72$) Androstenedione (nmol/l) 1.65 ($1.39-1.92$) 0.001^{a} $2.71-3.66$) Insulin (mU/l) 4.83 ($4.03-5.63$) 0.01^{a} 25.3 ($2.7-27.9$) C v v v v Age (yr) 12.1 ($12.0-12.1$) NS^{a} 12.1 ($12.0-12.1$) Age (yr) 12.1 ($12.0-12.1$) NS^{a} 160.1 ($12.0-12.1$) Height (cm) 153.3 ($0.35-0.20$) 0.001^{a} 0.88 ($0.48-1.28$) Height SDS -0.08 ($0.35-0.20$) 0.001^{a} 0.88 ($0.48-1.28$) Height (kg) 45.4 ($2.6-48.2$) 0.001^{a} 56.0 ($51.4-60.6$) BMI (kg/m ²) 19.2 ($18.2-20.1$) 0.01^{a} 21.6 ($20.3-23.0$) </td <th>Gestational age (weeks)</th> <td></td> <td>NS^a</td> <td></td>	Gestational age (weeks)		NS ^a	
Birth length (cm) (49.5–50.9) NS° (48.5–50.4) B I I I Age (yr) 7.5 (7.3–7.7) NS° 7.6 (7.3–7.8) Height SDS 0.16 (0.46–0.14) 0.001^6 1.02 (0.64–1.40) BMI SDS 0.18 (-0.11–0.47) 0.001^6 1.04 (0.65–1.43) DHEAS (µmol/I) 0.94 (0.79–1.09) 0.001^8 2.33 (1.94–2.72) Androstenedione (nmol/I) 1.65 (1.39–1.92) 0.001^8 2.33 (1.94–2.72) Insulin (mU/I) 4.83 (4.03–5.63) 0.01^8 5.98 (5.14–6.83) IGF-1 (nmol/I) 20.3 (18.5–22.1) 0.01^8 25.3 (22.7–27.9) Q 1 $15.3.3$ (18.5–22.1) 0.01^8 12.1 (12.0–12.1) Age (yr) 153.3 (151.4–155.2) 0.01^8 160.1 (157.4–162.9) Height Cm) 153.3 ($0.35–0.20$) 0.001^8 0.88 ($0.48–1.28$) Weight (kg) 45.4 ($42.6–48.2$) 0.001^8 56.0 ($51.4–60.6$) BMI (kg/m2) 19.2 ($18.2–20.1$) 0.01^8 0.81	Birth weight (kg)		NS ^a	
Age (yr) $(7.3-7.7)$ NS^3 $(7.3-7.8)$ Height SDS $\stackrel{-0.16}{(.0.46-0.14)}$ $\circ.001^{10}$ 1.02 $(0.64-1.40)$ BMI SDS 0.18 $(.0.11-0.47)$ $\circ.001^{10}$ 1.04 $(0.65-1.43)$ DHEAS (µmol/l) 0.94 $(0.79-1.09)$ $\circ.001^{10}$ 2.33 $(1.94-2.72)$ Androstenedione (nmol/l) 1.65 $(1.39-1.92)$ $\circ.001^{10}$ 2.33 $(1.94-2.72)$ Androstenedione (nmol/l) 1.65 $(1.39-1.92)$ $\circ.001^{10}$ 3.18 $(2.71-3.66)$ Insulin (mU/l) 4.83 $(4.03-5.63)$ $\circ.01^{10}$ 25.3 $(22.7-27.9)$ C 7 7 7 Age (yr) 12.1 $(12.0-12.1)$ NS^{10} 12.1 $(12.0-12.1)$ Height (cm) 153.3 $(151.4-155.2)$ $\circ.001^{10}$ 0.888 $(0.48-1.28)$ Height KSDS $\circ.0.08$ $(-0.35-0.20)$ $\circ.001^{10}$ 0.888 $(0.48-1.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $\circ.001^{10}$ 56.0 $(51.4-60.6)$ BMI (kg/m2) 19.2 $(18.2-20.1)$ $\circ.01^{10}$ 21.6 $(20.3-23.0)$	Birth length (cm)		NS ^b	
Age (yr) $(7.3-7.7)$ NS^3 $(7.3-7.8)$ Height SDS $\stackrel{-0.16}{(.0.46-0.14)}$ $\circ.001^{10}$ $\stackrel{1.02}{(0.64-1.40)}$ BMI SDS 0.18 $\circ.001^{10}$ $\stackrel{1.04}{(0.65-1.43)}$ DHEAS (µmol/l) 0.94 $\circ.001^{10}$ $\stackrel{2.33}{(1.94-2.72)}$ Androstenedione 1.65 $\circ.001^{10}$ $\stackrel{2.73}{(2.71-3.66)}$ Insulin (mU/l) 4.83 $\circ.001^{10}$ $\stackrel{2.53}{(2.71-3.66)}$ Insulin (mU/l) $\stackrel{2.03}{(1.85-22.1)}$ $\circ.01^{10}$ $\stackrel{2.53}{(22.7-27.9)}$ C 12.1 NS^{10} $\stackrel{1.21}{(12.0-12.1)}$ Age (yr) $\stackrel{1.53.3}{(151.4-152.2)}$ $\circ.001^{10}$ $\stackrel{1.60.1}{(157.4-162.9)}$ Height Cm) $\stackrel{1.53.3}{(151.4-155.2)}$ $\circ.001^{10}$ $\stackrel{0.88}{(0.48-1.28)}$ Weight (kg) $\stackrel{4.5.4}{(42.6-48.2)}$ $\circ.001^{10}$ $\stackrel{0.88}{(2.3-23.0)}$ BMI (kg/m²) $\stackrel{1.9.2}{(18.2-20.1)}$ $\sim.01^{10}$ $\stackrel{21.6}{(20.3-23.0)}$ BMI SDS 0.13 $\circ.01^{10}$ 0.81	В			
Height SDS(-0.460.14) $<0.001^{b}$ (0.641.40)BMI SDS 0.18 (-0.110.47) $<0.001^{b}$ 1.04 (0.651.43)DHEAS (µmol/l) 0.94 (0.791.09) $<0.001^{a}$ 2.33 (1.942.72)Androstenedione (nmol/l) 1.65 (1.391.92) $<0.001^{a}$ 3.18 (2.713.66)Insulin (mU/l) 4.83 (4.035.63) $<0.01^{a}$ 5.98 (5.146.83)IGF-1 (nmol/l) 20.3 (1.8.522.1) $<0.01^{a}$ 25.3 (22.727.9)C $<$ $<$ $<$ Age (yr) 12.1 (12.012.1) NS^{a} 12.1 (12.012.1)Height (cm) 153.3 (-0.35-0.20) $<0.001^{b}$ 0.88 (0.481.28)Weight (kg) 45.4 (42.648.2) $<0.001^{a}$ 56.0 (51.460.6)BMI (kg/m²) 19.2 (18.220.1) $<0.01^{a}$ 21.6 (20.323.0)BMI SDS 0.13 $<$ 0.01^{b} 0.81	Age (yr)		NS ^a	
BMII SDS $(-0.110.47)$ $<0.001^{b}$ $(0.651.43)$ DHEAS (µmol/l) 0.94 $(0.791.09)$ $<0.001^{a}$ 2.33 $(1.942.72)$ Androstenedione (nmol/l) 1.65 $(1.391.92)$ $<0.001^{a}$ 3.18 $(2.713.66)$ Insulin (mU/l) 4.83 $(4.035.63)$ $<0.01^{a}$ 5.98 $(5.146.83)$ IGF-1 (nmol/l) 20.3 $(18.522.1)$ $<0.01^{a}$ 25.3 $(22.727.9)$ C $<$ $<$ $<$ Age (yr) 12.1 $(12.012.1)$ NS^{a} 12.1 $(12.012.1)$ Height (cm) 153.3 $(151.4155.2)$ $<0.001^{b}$ 160.1 $(157.4162.9)$ Height SDS -0.08 $(-0.350.20)$ $<0.001^{b}$ 0.88 $(0.481.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $<0.001^{a}$ 56.0 $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.220.1)$ $<0.01^{a}$ 21.6 $(20.323.0)$ BMI SDS 0.13 $<0.01^{b}$ 0.81	Height SDS		<0.001 ^b	
DHEAS (µmol/l) $(0.79-1.09)$ $<0.001^{a}$ $(1.94-2.72)$ Androstenedione (nmol/l) 1.65 $(1.39-1.92)$ $<0.001^{a}$ 3.18 $(2.71-3.66)$ Insulin (mU/l) 4.83 $(4.03-5.63)$ $<0.01^{a}$ 5.98 $(5.14-6.83)$ IGF-1 (nmol/l) 20.3 $(18.5-22.1)$ $<0.01^{a}$ 25.3 $(22.7-27.9)$ C $<$ $<$ Age (yr) 12.1 $(12.0-12.1)$ NS^{a} 12.1 $(12.0-12.1)$ Height (cm) 153.3 $(151.4-155.2)$ $<0.001^{b}$ 160.1 $(157.4-162.9)$ Height KDS -0.08 $(-0.35-0.20)$ $<0.001^{b}$ 0.88 $(0.48-1.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $<0.001^{a}$ 56.0 $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.2-20.1)$ $<0.01^{a}$ 21.6 $(20.3-23.0)$ BMI SDS 0.13 $<0.01^{b}$ 0.81	BMI SDS		<0.001 ^b	
(nmol/l) $(1.39-1.92)$ $<0.001^{a}$ $(2.71-3.66)$ Insulin (mU/l) 4.83 $(4.03-5.63)$ $<0.01^{a}$ 5.98 $(5.14-6.83)$ IGF-1 (nmol/l) 20.3 $(18.5-22.1)$ $<0.01^{a}$ 25.3 $(22.7-27.9)$ C $<$ $<$ Age (yr) 12.1 $(12.0-12.1)$ NS^{a} 12.1 $(12.0-12.1)$ Height (cm) 153.3 $(151.4-155.2)$ $<0.001^{b}$ 160.1 $(157.4-162.9)$ Height SDS -0.08 $(-0.35-0.20)$ $<0.001^{b}$ 0.88 $(0.48-1.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $<0.001^{a}$ 56.0 $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.2-20.1)$ $<0.01^{a}$ 21.6 $(20.3-23.0)$ BMI SDS 0.13 $<0.01^{b}$ 0.81	DHEAS (µmol/l)		<0.001 ^a	
Insulin (mU/I) $(4.03-5.63)$ $<0.01^{a}$ $(5.14-6.83)$ IGF-1 (nmol/I) $20.3 \\ (18.5-22.1)$ $<0.01^{a}$ $25.3 \\ (22.7-27.9)$ C $<$ $<$ $<$ Age (yr) $12.1 \\ (12.0-12.1)$ NS^{a} $12.1 \\ (12.0-12.1)$ Height (cm) $153.3 \\ (151.4-155.2)$ $<0.001^{b}$ $160.1 \\ (157.4-162.9)$ Height SDS $-0.08 \\ (-0.35-0.20)$ $<0.001^{b}$ $0.88 \\ (0.48-1.28)$ Weight (kg) $45.4 \\ (42.6-48.2)$ $<0.001^{a}$ $56.0 \\ (51.4-60.6)$ BMI (kg/m²) $19.2 \\ (18.2-20.1)$ $<0.01^{a}$ $21.6 \\ (20.3-23.0)$ BMI SDS $0.13 \\ <0.01^{b}$ 0.81	Androstenedione (nmol/l)		<0.001 ^a	
IGF-1 (nmol/l) $(18.5-22.1)$ $<0.01^{a}$ $(22.7-27.9)$ CIIIIAge (yr) 12.1 $(12.0-12.1)$ NSa 12.1 $(12.0-12.1)$ Height (cm) 153.3 $(151.4-155.2)$ $<0.001^{b}$ 160.1 	Insulin (mU/I)		<0.01ª	
Age (yr) 12.1 $(12.0-12.1)$ NSa 12.1 $(12.0-12.1)$ Height (cm) 153.3 $(151.4-155.2)$ $<0.001^{b}$ 160.1 $(157.4-162.9)$ Height SDS -0.08 $(-0.35-0.20)$ $<0.001^{b}$ 0.88 $(0.48-1.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $<0.001^{a}$ 56.0 $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.2-20.1)$ $<0.01^{a}$ 21.6 $(20.3-23.0)$ BMI SDS 0.13 $<0.01^{b}$ 0.81	IGF-1 (nmol/l)		<0.01 ^a	
Age (yr)(12.0—12.1)NSa(12.0—12.1)Height (cm)153.3 (151.4—155.2)<0.001b160.1 (157.4—162.9)Height SDS-0.08 (-0.35—0.20)<0.001b0.888 (0.48—1.28)Weight (kg)45.4 (42.6—48.2)<0.001a56.0 (51.4—60.6)BMI (kg/m²)19.2 (18.2—20.1)<0.01a21.6 (20.3—23.0)BMI SDS0.13<0.01b0.81	С			
Height (cm) $(151.4-155.2)$ $<0.001^{\circ}$ $(157.4-162.9)$ Height SDS -0.08 $(-0.35-0.20)$ $<0.001^{\circ}$ 0.88 $(0.48-1.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $<0.001^{\circ}$ 56.0 $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.2-20.1)$ $<0.01^{\circ}$ 21.6 $(20.3-23.0)$ BMI SDS 0.13 $<0.01^{\circ}$ 0.81	Age (yr)		NS ^a	
Height SDS $(-0.35-0.20)$ $<0.001^{\circ}$ $(0.48-1.28)$ Weight (kg) 45.4 $(42.6-48.2)$ $<0.001^{\circ}$ 56.0 $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.2-20.1)$ $<0.01^{\circ}$ 21.6 $(20.3-23.0)$ BMI SDS 0.13 $<0.01^{\circ}$ 0.81	Height (cm)	153.3 (151.4—155.2)	<0.001 ^b	
Weight (kg) $(42.6-48.2)$ $<0.001^{a}$ $(51.4-60.6)$ BMI (kg/m²) 19.2 $(18.2-20.1)$ $<0.01^{a}$ 21.6 $(20.3-23.0)$ BMI SDS 0.13 $<0.01^{b}$ 0.81	Height SDS	-0.08 (-0.35—0.20)	<0.001 ^b	
BIVIT (kg/m²) $(18.2-20.1)$ $<0.01^{a}$ $(20.3-23.0)$ BIVIT SDS 0.13 $<0.01^{b}$ 0.81	Weight (kg)		<0.001ª	
S S S S S S S S S S S S S S S S S	BMI (kg/m²)		<0.01ª	
	BMI SDS		<0.01 ^b	

■ 1 ■ 2 ■ 3 ■ 4 ■ 5	■1■.	■ 2 ■ 3 ■ 4 ■ 5						
Table 2. Predictive factors for menarche by logistic regression analysis. Values are expressed as OR (95% CI).								
	Logistic regression analysis							
	Dependent variable: Menarche (yes or no)							
	Univariate	р	Multivariate	р				
Age (years)	0.41 (0.11—15.12)	0.63	Exc					
PA	5.17 (2.05—13.07)	<0.01	7.17 (1.24—41.34)	<0.05				
Maternal age at menarche (years)	0.26 (0.13—0.55)	<0.001	0.23 (0.08—0.67)	<0.01				
BMISDS	1.96 (1.29—2.96)	<0.01	Exc					
DHEAS (µmol/l)	1.72 (1.09—2.71)	<0.05	Exc					
Androstenedione (nmol/l)	1.70 (1.18—2.44)	<0.01	Exc					
Insulin (mU/I)	1.28 (1.06—1.55)	<0.05	Exc					
IGF-1 (nmol/l)	1.14 (1.06—1.23)	<0.001	1.15 (1.01—1.32)	<0.05				
	Multivariate	R square:	0.68					

DISCUSSION

Our PA girls had advanced pubertal development and linear growth, and they had remained slightly heavier compared to control girls at 12 years of age. In boys, larger cohorts need to be evaluated. Future research will show if these chances in body composition persist into adulthood. Prepubertal

Figure 2. Percentage of pubertal children at 12 years of age among PA and control girls and boys.										
	Thelarche and testicular growth (Tanner B \geq 2 or testicular size \geq 4 ml)			Pubarche (Tanner P ≥ 2)			Menarche			
100% -	χ2	NS	χ2	NS	x 2 <	0.01	χ2	NS	x 2 <	0.001
80% -			Yes;	Yes;			Yes;		Yes; 25%	
60% -	Yes;	Yes;	45%	43%	Yes;	Voc	33%	Yes; 71%		Yes; 64%
40% -	93%	97%		- No.	82%	Yes; 100%	- No; -	-	No;	
20%	No; 7%	No; 3%	No; 55%	No; 57%	No; 18%	No; 0%	67%	No; 29%	75%	No; 36%
0% -	Control girls	PA girls	Control Boys	PA boys	Control girls	PA girls	Control Boys	PA boys	Control girls	PA girls
n	51	36	11	7	51	36	9	7	51	36

serum IGF1 level and the history of PA are associated with earlier timing of menarche.

REFERENCES

- . Premature adrenarche a common condition with variable presentation. Utriainen et al. *Horm Res Paediatr* 2015.
- 2. The relationship between insulin-like growth factor 1, sex steroids and timing of the pubertal growth spurt. Cole et al. *Clin Endocrinol 2015.*
- 3. Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors. Sopher et al. *Obesity 2011.*
- 4. Early puberty-menarche after precocious pubarche: relation to prenatal growth. Ibanez et al. *Pediatrics 2006.*
- 5. Follow up of growth and steroids in premature adrenarche. Pere et al. *Eur J Pediatr 1995.*

